Akari Therapeutics Plc Valor contable por acción
¿Qué es el Valor contable por acción de Akari Therapeutics Plc?
El Valor contable por acción de Akari Therapeutics Plc es 0.05
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Akari Therapeutics Plc
¿Qué hace Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Empresas con valor contable por acción similar a Akari Therapeutics Plc
- Altiplano Metals tiene Valor contable por acción de 0.05
- Bitterroot Resources tiene Valor contable por acción de 0.05
- Cinaport Acquisition III tiene Valor contable por acción de 0.05
- Greenfield Acquisition Corp tiene Valor contable por acción de 0.05
- Easy Repay Finance & Investment tiene Valor contable por acción de 0.05
- Baselode tiene Valor contable por acción de 0.05
- Akari Therapeutics Plc tiene Valor contable por acción de 0.05
- Timberline Resources tiene Valor contable por acción de 0.05
- Four Nines Gold tiene Valor contable por acción de 0.05
- AAJ Capital 2 tiene Valor contable por acción de 0.05
- Castile Resources tiene Valor contable por acción de 0.05
- Zhuoxin International tiene Valor contable por acción de 0.05
- Asian Television Network International tiene Valor contable por acción de 0.05